Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06015295 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy

StatusTerminated
PhaseNot applicable
Started2024-11-07
View on ClinicalTrials.gov ↗

Amendment history

2026-09-24
Trial terminated: \<\&%% participation
Primary completion confirmed: September 2026 (last estimated March 2028)
2026-06-01
Study Status, Study Design, Contacts/Locations v6
Trial status changed: Recruiting → Active, Not Recruiting
Enrollment reduced: 20 → 3 participants
Study sitesdetails revised at 1 of 1 site
2026-04-10
2 amendments v4-v5
2 re-verifications since 2025-10-23, no change to tracked fields
2025-05-12
Study Status v3
Primary completion date2025-03-31→2028-03-30
Completion date2027-03-31→2028-03-30
2024-11-18
Study Identification, Study Status v2
Re-verified, no change to tracked fields
2024-11-15
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-02-28→confirmed 2024-11-07
Study sitesdetails revised at 1 of 1 site
2023-08-23
Original filing
To learn if 18F-Fluciclovine (Axumin) PET-CT scans can be used to better detect brain metastatic lesions in patients who are receiving immunotherapy.
Trial Details
NCT Number NCT06015295
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Blue Earth Diagnostics
Conditions Brain Metastases
Enrollment 3 participants
Start Date 2024-11-07
Primary Completion 2026-09-17 (estimated)
Study Completion 2026-09-17 (estimated)
Updated on ClinicalTrials.gov 2026-09-23